The Lancet Conference Alerts | Have you read our AHA Scientific Sessions 2025 content? ++ ++

ARTICLES Efficacy and safety of REGN9933A² and REGN7508Cat for preventing postoperative venous thromboembolism (ROXI-VTE-I and ROXI-VTE-II): two randomised, open-label, phase 2 trials Free to access with registration until Nov 18, 2025 https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)02097-5/abstract?utm_campaign=conferencealerts&utm_medium=email&dgcid=hubspot_email_conferencealerts_aha25&_hsenc=p2ANqtz-9NVeFdl6PepHnjoDReDX85pE6seSHLf-fSIL6WLcZGTgif2pPPAi-sfWZGd8IhHpm7DDfUPh7L_qIOqc8OS6BWnGgpqg&_hsmi=389170563&utm_content=389170563&utm_source=hs_email Complete versus culprit lesion-only revascularisation for acute myocardial infarction (Complete Revascularisation Trialists’ Collaboration): an individual patient data meta-analysis of randomised trials Free to access with registration until Nov 18, 2025 https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)02170-1/abstract?utm_campaign=conferencealerts&utm_medium=email&dgcid=hubspot_email_conferencealerts_aha25&_hsenc=p2ANqtz-_fbj_oOEiyHHRDM-Way_bKhBEL5LUGiz1KsuXyLcn1dhIU1wiigtpwVOwS35YgD31P-mhu3arpyXEKXKUsy80u8UuWrQ&_hsmi=389170563&utm_content=389170563&utm_source=hs_email COMMENTS New light on the activators of factor XI in venous thromboembolism Free to access with registration until Nov 18, 2025 https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)02256-1/abstract?utm_campaign=conferencealerts&utm_medium=email&dgcid=hubspot_email_conferencealerts_aha25&_hsenc=p2ANqtz--DdvQzfwUtgMdDDwyfR0a-TtCt3EwCun6rCUP5V2BfgIJZyRgxkl8U7wfHR45kW0MojNw2-OrNwtl49U6hdmknMJdveA&_hsmi=389170563&utm_content=389170563&utm_source=hs_email Complete revascularisation in patients with acute myocardial infarction Free to access with registration until Nov 18, 2025 https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)02243-3/abstract?utm_campaign=conferencealerts&utm_medium=email&dgcid=hubspot_email_conferencealerts_aha25&_hsenc=p2ANqtz-_btrFJHiI-fwbEZTRphNuQcRYYpvgjAUPaANS5W0If4q9KRJp9z5CsVj-0reYlK6gmfUqF-jOGVrVEQQFy9uaS8KPR7Q&_hsmi=389170563&utm_content=389170563&utm_source=hs_email